Lipella Pharmaceuticals has the GF Score of 35, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Lipella Pharmaceuticals
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Lipella Pharmaceuticals GF Score Related Terms
LIPO vs IOBTQ, WINT, CYTOF: GF Score Comparison
For the Biotechnology subindustry, Lipella Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's GF Score distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's GF Score falls into.
Lipella Pharmaceuticals (LIPO) has a GF Score of 35 as of Jul. 01, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Lipella Pharmaceuticals and its competitors. This is 84% above median its historical median of 19.00. Over the past decade, Lipella Pharmaceuticals' GF Score has ranged from 11.00 to 44.00.
Is Lipella Pharmaceuticals' GF Score too high?
Lipella Pharmaceuticals' current GF Score of 35 is 84% above median its 10-year median of 19.00. Over the past 10 years, this metric has ranged from a low of 11.00 to a high of 44.00. Overall, Lipella Pharmaceuticals has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lipella Pharmaceuticals' GF Score compare to IOBTQ and WINT?
Lipella Pharmaceuticals' GF Score of 35 can be compared against companies in the Biotechnology industry. Historically, Lipella Pharmaceuticals' own GF Score has ranged from 11.00 to 44.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current GF Score is 35, which is 84% above median its own 10-year median of 19.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.68, compared to a current price of $0.13 — trading 98.5% below its estimated fair value. The current GF Score is 35, which is 84% above median its 10-year median of 19.00. Lipella Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current GF Score is 35 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipella Pharmaceuticals (LIPO) Overvalued in 2026?
Based on GuruFocus' analysis, Lipella Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.13 is trading 98.5% below its estimated GF Value™ of $8.68.
GuruFocus considers Lipella Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LIPO:
GF Score: 35 (84% above median its 10-year median of 19.00)
GF Value™: $8.68 vs. price of $0.13 (98.5% below fair value)
No single metric tells the full story. See the LIPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
35GF Score
Get the complete analysis for LIPO
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 